logo
The Best Time to Eat Breakfast for Weight Loss, According to Dietitians

The Best Time to Eat Breakfast for Weight Loss, According to Dietitians

Yahooa day ago
Reviewed by Dietitian Kelly Plowe, M.S., RDEating early in the day and front-loading your calories supports greater weight loss versus eating later.
Experts suggest eating breakfast at least 12 hours after your last meal for the most benefits.
Breakfast is linked to better diet quality, cognitive benefits and reduced risk of cardiovascular disease.You've probably heard that breakfast is the most important meal of the day. And experts agree that, in most cases, some breakfast is better than no breakfast. That's because skipping breakfast is associated with an increased risk of obesity, insulin resistance and metabolic syndrome.
But does it matter when we eat breakfast?
Emerging research suggests that meal timing is important, especially for weight loss. 'Studies show that front-loading calories earlier in the day supports greater weight loss, even under the same daily calorie intake,' says Lindsay Fencl, RD, CD. Here's what dietitians have to say about the best time to eat breakfast, why eating earlier might be better and the many other benefits of breakfast.
Eating earlier in the day aligns naturally with your circadian rhythm, the body's internal clock, which regulates the sleep-wake cycle, hormone release and metabolism. In other words, our bodies are more efficient earlier in the day, when it comes to digesting food and burning calories, as compared to the latter part of the day.
It makes sense when you think about it: Food provides fuel, and you need that energy when you're awake during the day versus when you're sleeping at night. In fact, studies show that late-night eating is associated with weight gain and increased risk of chronic diseases like diabetes.
But when should we eat breakfast? 'There is not an exact time that is best to have breakfast, as this may depend on the person and their typical schedule,' says Melissa Mitri, M.S., RD. 'However, it's clear that eating something matters, as research suggests a connection to eating earlier and greater weight loss.'
Mitri does suggest waiting to eat breakfast until at least 12 hours after your previous meal as a good starting point, due to the metabolic benefits of an overnight fast. 'For example, if you ate dinner at 7 p.m., then your breakfast would be at 7 a.m. or later,' explains Mitri.
There is one study that found a sweet spot when it comes to specific breakfast timing and weight loss. Results of the study showed that eating breakfast between 6:45 and 7:30 a.m. led to more weight loss over 12 weeks versus eating breakfast between 8:10 and 9:10 a.m. Caveat: This was one study. More research needs to be done to validate these findings.
Eating breakfast could protect your brain from age-related cognitive decline. A recent study provided cognitive tests to more than 850 adults every 18 months. The researchers also looked for signs of neurodegeneration. The results showed that breakfast skippers did not perform as well on the cognitive tests compared to those who ate breakfast. Those who skipped the first meal of the day were also at greater risk of experiencing cognitive decline and signs of neurodegeneration.
'A quality breakfast, ideally consumed within two to three hours of waking, is linked to a wide range of health benefits, including better mood, improved cognitive function, smarter food choices and more effective weight management,' says Fencl.
Eating breakfast may lead to eating a higher-quality diet overall. Research shows that skipping breakfast led to a two-point decrease in Healthy Eating Index Scores. Missing the first meal of the day lowered scores in the fruit, whole grain, dairy and empty calories categories.
A quality breakfast can also do your heart some good. A clinical trial found that subjects who consumed 20% to 30% of their total calories at breakfast had lower BMIs and smaller waistlines, along with a 9% to 18% reduction in triglyceride levels and a 4% to 8% increase in HDL cholesterol levels.
In addition to eating a balanced breakfast early in the day, and at least 12 hours after your last meal, follow these other habits for successful weight management.
Eat a balanced lunch and dinner. At most lunches and dinners, aim to follow the balanced plate framework, making half your plate vegetables, a quarter of your plate whole grains and a quarter of your plate protein. This helps keep you full and satisfied.
Eat mostly whole foods. Choose whole foods like fruits, vegetables, whole grains, lean proteins, nuts, seeds and legumes. These foods not only pack protein and fiber to keep you full, but also provide important vitamins, minerals and antioxidants that keep inflammation at bay. Consume refined sugars in moderation.
Get your steps in. Walking is one of the most underrated forms of exercise for weight loss. Research shows that walking for 50 minutes, just four times a week (at moderate to vigorous intensity) can help with weight loss and losing fat in the belly region.
Lift weights. Strength training helps build and preserve lean muscle mass. When you lose weight, you lose both fat and muscle, unless you're doing something to preserve that muscle mass. Less muscle means a slower metabolism. The Centers for Disease Control and Prevention recommends strength training at least two days per week.
Get seven to nine hours of good-quality sleep. Sleep is just as important as diet and exercise when it comes to weight loss. Research shows that just one night of sleep deprivation decreases leptin, the satiety hormone, and increases ghrelin, the hunger hormone. This may lead to more snacking the next day, specifically on foods higher in fat and carbohydrates.
Manage stress. Stress leads to elevated cortisol, the stress hormone. The carbs you crave when you're stressed? It's biological. Cortisol increases cravings for sugary and fatty foods. Elevated cortisol is also associated with an increase in belly fat. Practicing mindfulness techniques, meditation and exercise can all help reduce stress, which can impact weight loss.
Eating breakfast early in the day aligns with your circadian rhythm. Your body is more efficient in the first part of the day at digesting food and burning calories compared to the latter. When it comes to timing, experts suggest waiting at least 12 hours after your last meal. Eating breakfast is also associated with a better-quality diet, short- and long-term cognitive benefits and a reduced risk of cardiovascular disease.
Read the original article on EATINGWELL
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Yahoo

time31 minutes ago

  • Yahoo

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Company will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species (MUMS) designation request to the United States Food and Drug Administration (FDA) for tafenoquine for the treatment of acute canine babesiosis. The submission will be based on results of three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, and existing canine safety data and chemistry manufacturing and controls (CMC) data for tafenoquine generated through the clinical development of ARAKODA for malaria. The clinical efficacy studies involved experimental Babesia infections and dogs diagnosed with naturally acquired Babesia infection in veterinary clinics. One of the studies was company-sponsored and conducted at North Carolina State University. Collectively, the studies showed that tafenoquine, administered as ARAKODA tablets, was well tolerated and appeared to facilitate recovery from acute infection. Every year in the United States, several hundred to several thousand cases of canine babesiosis are seen. It is an emerging tick-borne illness carried by the same tick vector as Lyme Disease. No FDA-approved oral treatment for canine babesiosis exists, and currently available treatments carry significant toxicity risk or the propensity to generate drug resistance. 'Data from the canine babesiosis studies are impactful when viewed in the larger context of the ground-breaking human babesiosis research we are now sponsoring,' said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow. 'The positive findings of the canine babesiosis study are in line with our earlier findings that tafenoquine could be effective against babesiosis in humans.' About ARAKODA® (tafenoquine)Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication. ARAKODA® (tafenoquine) Important Safety Information ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. Contraindications ARAKODA® should not be administered to: Glucose-6-phosphate dehydrogenase ('G6PD') deficiency or unknown G6PD status; Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown; Patients with a history of psychotic disorders or current psychotic symptoms; or Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®. Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant's G6PD status before breastfeeding begins. Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible. Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy. Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety. Drug Interactions Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters. Use in Specific Populations Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or The full prescribing information of ARAKODA® is located here. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts:Sheila A. BurkeSheilaBurke-consultant@ 667-6330 Investor Contact:Patrick Gaynespatrickgaynes@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'
New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

Yahoo

timean hour ago

  • Yahoo

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

A New Jersey woman says she almost died after taking daily turmeric pills, a popular supplement found in grocery stores. Katie Mohan, a 57-year-old from Morristown, told she sustained liver damage after taking daily pills of turmeric, a yellow spice widely used for its antioxidant and anti-inflammatory properties. Mohan said her first symptoms included fatigue, nausea, stomach pain and yellowing eyes, which are a sign of jaundice. Mohan first saw her doctor in April, but the scans and tests ordered came back normal. Her symptoms continued to get worse until June, when Mohan read an NBC News story about a man with similar symptoms who found out he had a drug-induced liver injury after taking turmeric daily. 'I threw [the supplements] out, and I said to myself, 'I'm wondering if this is what's causing my symptoms,'' Mohan told Mohan bought the turmeric pills, which were manufactured by YouTheory, at Costco, reports. The product states the daily dose is three pills containing 2,250 milligrams, Mohan said, which is over the World Health Organization's recommendation of up to 3 milligrams per kilogram of body weight per day. A New Jersey woman says she damaged her liver by taking daily turmeric supplements (Getty Images) After reading the NBC News article, Mohan went to urgent care. From there, she was admitted to Morristown Medical Center, where doctors found that she had severe liver damage. She was treated with an antiviral IV drip, but her skin was still yellowing. Mohan recalled thinking: 'Am I going to need a liver transplant? Am I going to die?' 'I was very, very, very scared,' she added. That's when she was transferred to NYU Langone in New York. There, her doctor found 'evidence of acute hepatitis, impending liver failure and potential transplant evaluation.' 'She was really very sick,' Dr. Nikolaos Pyrsopoulos, told 'Her liver numbers were 60 to 70 times above the normal limit. And she was very yellow.' Mohan said Pyrsopoulos confirmed her fears that the turmeric caused her symptoms. Katie Mohan said she was worried she would need a liver transplant after taking too much turmeric (Getty Images) 'He's like, 'You essentially poisoned the liver with the turmeric,'' she said. 'It was the dose combined with the fact that it had that black pepper in it.' Pyrsopoulos told that his hospital sees three to four liver transplants per year related to turmeric poisoning. Mohan has since been discharged and says her liver enzyme levels are still elevated, but they're continuing to fall and her symptoms have completely disappeared. Mohan has since reported the supplements to the Food and Drug Administration. The Independent has contacted Costco and YouTheory for comment.

New York official again rebuffs Texas judgment against doctor over abortion pills
New York official again rebuffs Texas judgment against doctor over abortion pills

Yahoo

timean hour ago

  • Yahoo

New York official again rebuffs Texas judgment against doctor over abortion pills

By Daniel Wiessner (Reuters) -A county official in New York on Monday rejected for a second time efforts by Texas to enforce a $100,000 judgment against a New York doctor accused of violating Texas' ban on abortion by sending abortion pills to the state, further escalating an unprecedented interstate conflict. Acting Ulster County Clerk Taylor Bruck in a letter to the office of Republican Texas Attorney General Ken Paxton doubled down on his March finding that New York's so-called shield law precludes the enforcement of other states' abortion bans against New Yorkers. Paxton's office last week had asked Bruck to reconsider, arguing that he had a legal duty to enforce the judgment against New Paltz, New York-based doctor Margaret Carpenter. Bruck on Monday said Paxton's office had not presented any new information. "While I'm not entirely sure how things work in Texas, here in New York, a rejection means the matter is closed," wrote Bruck, who is running for county clerk as a Democrat. Paxton's office and the Abortion Coalition for Telemedicine, a group co-founded by Carpenter, did not immediately respond to requests for comment. New York Governor Kathy Hochul, a Democrat who championed the passage of the shield law earlier this year, praised Bruck for "defending the freedom generations of women fought to secure." "Our response to (Texas') baseless claim is clear: no way in hell. New York won't be bullied," Hochul said in a statement. Medication abortion accounts for more than half of U.S. abortions. It has drawn increasing attention since the U.S. Supreme Court's 2022 decision allowing states to ban abortion, which more than 20 states, including Texas, have done. A judge in Collin County, Texas, entered a default judgment against Carpenter in February after she failed to respond to the state's civil lawsuit alleging she illegally prescribed mifepristone and misoprostol, the two drugs used in medication abortion, to a Texas woman via telemedicine. Carpenter has also been indicted by a Louisiana grand jury for prescribing an abortion pill that was taken by a teenager there, in what appeared to be the first time a state criminally charged a doctor in another state for prescribing abortion drugs. Hochul in February rejected Louisiana's request to extradite Carpenter there.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store